ロード中...
The unfolding treatment landscape for men with castration-resistant prostate cancer
Castration-resistant prostate cancer (CRPC) is a fatal disease in virtually all patients. Docetaxel chemotherapy became the standard front-line agent based on the results of the TAX327 trial in 2004, with a survival advantage of 3 months achieved over mitoxantrone. Over the past few years, an improv...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2011
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3483028/ https://ncbi.nlm.nih.gov/pubmed/23115711 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4155/cli.11.138 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|